Hormone Receptor Positive

Disease

Related News

T-DXd Reshapes Treatment Sequencing in HER2-Positive Metastatic Breast Cancer

Mar 21, 2026

Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.

HER2-Positive Breast Cancer Treatment Advances in First-Line and Neoadjuvant Settings

Feb 17, 2026

New clinical trial data show trastuzumab deruxtecan plus pertuzumab extends progression-free survival as first-line therapy, while MRI-guided treatment shortening reduces toxicity in neoadjuvant settings for HER2-positive breast cancer.